BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23449448)

  • 1. Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells.
    Kao C; Chao A; Tsai CL; Lin CY; Chuang WC; Chen HW; Yen TC; Wang TH; Lai CH; Wang HS
    Cell Death Dis; 2013 Feb; 4(2):e512. PubMed ID: 23449448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells.
    Selimovic D; Porzig BB; El-Khattouti A; Badura HE; Ahmad M; Ghanjati F; Santourlidis S; Haikel Y; Hassan M
    Cell Signal; 2013 Jan; 25(1):308-18. PubMed ID: 23079083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer.
    Uddin S; Ahmed M; Hussain AR; Jehan Z; Al-Dayel F; Munkarah A; Bavi P; Al-Kuraya KS
    Lab Invest; 2009 Oct; 89(10):1115-27. PubMed ID: 19636294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
    Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
    Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.
    Kawabata S; Gills JJ; Mercado-Matos JR; Lopiccolo J; Wilson W; Hollander MC; Dennis PA
    Cell Death Dis; 2012 Jul; 3(7):e353. PubMed ID: 22825471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
    Tsapakidis K; Vlachostergios PJ; Voutsadakis IA; Befani CD; Patrikidou A; Hatzidaki E; Daliani DD; Moutzouris G; Liakos P; Papandreou CN
    Int J Urol; 2012 Jun; 19(6):565-74. PubMed ID: 22324515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of CIP2A in the antitumor effect of bortezomib in colon cancer.
    Ding Y; Wang Y; Ju S; Wu X; Zhu W; Shi F; Mao L
    Mol Med Rep; 2014 Jul; 10(1):387-92. PubMed ID: 24789441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Requirement for endogenous heat shock factor 1 in inducible nitric oxide synthase induction in murine microglia.
    Huang C; Lu X; Tong L; Wang J; Zhang W; Jiang B; Yang R
    J Neuroinflammation; 2015 Oct; 12():189. PubMed ID: 26467650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune mechanism of the antitumor effects generated by bortezomib.
    Chang CL; Hsu YT; Wu CC; Yang YC; Wang C; Wu TC; Hung CF
    J Immunol; 2012 Sep; 189(6):3209-20. PubMed ID: 22896634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.
    Vangala JR; Dudem S; Jain N; Kalivendi SV
    J Biol Chem; 2014 May; 289(18):12612-22. PubMed ID: 24627483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death.
    Kim SY; Song X; Zhang L; Bartlett DL; Lee YJ
    Biochem Pharmacol; 2014 Mar; 88(2):178-88. PubMed ID: 24486574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells.
    Lesinski GB; Benninger K; Kreiner M; Quimper M; Young G; Carson WE
    Cancer Immunol Immunother; 2009 Dec; 58(12):2031-7. PubMed ID: 19396596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short interfering RNA against STAT1 attenuates cisplatin-induced ototoxicity in the rat by suppressing inflammation.
    Kaur T; Mukherjea D; Sheehan K; Jajoo S; Rybak LP; Ramkumar V
    Cell Death Dis; 2011 Jul; 2(7):e180. PubMed ID: 21776018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The proteasome inhibitor bortezomib is a potent inducer of zinc finger AN1-type domain 2a gene expression: role of heat shock factor 1 (HSF1)-heat shock factor 2 (HSF2) heterocomplexes.
    Rossi A; Riccio A; Coccia M; Trotta E; La Frazia S; Santoro MG
    J Biol Chem; 2014 May; 289(18):12705-15. PubMed ID: 24619424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MACC1 regulates Fas mediated apoptosis through STAT1/3 - Mcl-1 signaling in solid cancers.
    Radhakrishnan H; Ilm K; Walther W; Shirasawa S; Sasazuki T; Daniel PT; Gillissen B; Stein U
    Cancer Lett; 2017 Sep; 403():231-245. PubMed ID: 28649004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.
    Baran-Marszak F; Boukhiar M; Harel S; Laguillier C; Roger C; Gressin R; Martin A; Fagard R; Varin-Blank N; Ajchenbaum-Cymbalista F; Ledoux D
    Haematologica; 2010 Nov; 95(11):1865-72. PubMed ID: 20663948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
    Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of heat shock protein response enhances PS-341-mediated glioma cell death.
    Liu Y; Zheng T; Zhao S; Liu H; Han D; Zhen Y; Xu D; Wang Y; Yang H; Zhang G; Wang C; Wu J; Ye Y
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S421-9. PubMed ID: 21732139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells.
    Carmo CR; Lyons-Lewis J; Seckl MJ; Costa-Pereira AP
    PLoS One; 2011; 6(5):e19861. PubMed ID: 21625473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.